ReNeuron Group PLC
LSE:RENE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ReNeuron Group PLC
Cash from Operating Activities
ReNeuron Group PLC
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
ReNeuron Group PLC
LSE:RENE
|
Cash from Operating Activities
-£5.3m
|
CAGR 3-Years
22%
|
CAGR 5-Years
19%
|
CAGR 10-Years
2%
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash from Operating Activities
-£10.7m
|
CAGR 3-Years
25%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Cash from Operating Activities
-$157.2m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Cash from Operating Activities
£64.4m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
12%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Cash from Operating Activities
£507k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Niox Group PLC
LSE:NIOX
|
Cash from Operating Activities
£15.4m
|
CAGR 3-Years
32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ReNeuron Group PLC
Glance View
ReNeuron Group Plc engages in the development of novel cell based therapies that target significant areas of unmet medical need. The company is headquartered in Bridgend, Glamorgan and currently employs 43 full-time employees. The company went IPO on 2005-08-12. The firm develops allogeneic stem cell technology platforms, stem cell derived exosomes and induced pluripotent stem cells. The firm's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). The firm's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. The company is engaged in Phase II clinical trial of CTX cells for stroke disability. The company is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. The company is engaged in Phase I clinical trial of hRPC stem cell candidate.
See Also
What is ReNeuron Group PLC's Cash from Operating Activities?
Cash from Operating Activities
-5.3m
GBP
Based on the financial report for Sep 30, 2023, ReNeuron Group PLC's Cash from Operating Activities amounts to -5.3m GBP.
What is ReNeuron Group PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
2%
Over the last year, the Cash from Operating Activities growth was 26%. The average annual Cash from Operating Activities growth rates for ReNeuron Group PLC have been 22% over the past three years , 19% over the past five years , and 2% over the past ten years .
